- 6-12 months initial treatment
- 8-12 weeks for initial response; ongoing management through growth
- 75%
China versus the U.S.
- China clinical rate
- $800 – $4,000
- $2,400
- United States
- $3,000 – $16,000
- $9,500
- You save
- ~75%
- $7,100 per procedure
Prices are approximate ranges. Actual cost depends on hospital, surgeon, materials, and case complexity.
What the procedure involves.
Specialized pediatric rheumatology care for juvenile idiopathic arthritis (JIA) using biologic agents, methotrexate, and rehabilitation programs designed for growing children. China's pediatric rheumatology centers provide family-centered care with expertise in all JIA subtypes. Treatment goals include disease remission, normal growth, and prevention of joint damage.
Step by step.
Pediatric Rheumatology Assessment
Joint examination, growth evaluation, eye screening for uveitis, laboratory workup, and JIA subtype classification
First-line Treatment
NSAIDs and intra-articular corticosteroid injections for oligoarticular disease; methotrexate for polyarticular involvement
Biologic Escalation
TNF inhibitors (etanercept, adalimumab) or IL-6 blockers (tocilizumab) for inadequate DMARD response
Growth & Rehabilitation Monitoring
Regular growth assessments, ophthalmology screening, physical therapy, and psychosocial support
- Affordable biologic therapy for pediatric patients
- Family-centered care with parent education programs
- Growth monitoring integrated into treatment planning
- Access to pediatric rheumatology specialists
- Growth impacts from chronic inflammation or steroid use
- Uveitis risk requiring regular eye screening
- Long-term immunosuppression in developing immune systems
- Psychological impacts on child development
Ask the AI for hospitals that handle juvenile arthritis treatment.
Prices shown are approximate ranges for reference only. Actual costs vary by hospital, complexity, and individual patient needs. Always consult with healthcare professionals for medical decisions.